The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study
OncoImmunology | June 2, 2025 | Volume: 14 | Issue: 1 | Pages: No page available
10.1080/2162402x.2025.2513106
| PMID 40452181